for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Semnur Pharmaceuticals announces successful phase 1/2 trial for its lead product, SP-102

June 26 (Reuters) - Semnur Pharmaceuticals Inc:

* trial also showed that adverse events were comparable between two treatments

* Semnur pharmaceuticals inc announces successful phase 1 / 2 trial in patients with radicular pain for its lead product, SP-102

* trial was conducted in patients with radicular pain, achieved its primary pharmacokinetic endpoint

* announced successful phase 1 / 2 pharmacokinetic bridging trial of lead product SP-102 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up